Molecular Docking and Interaction of Coumarin Derivatives as Inhibitors of Growth Factor Receptors


  • SAMEER SHARMA Indian Academy Degree College - Autonomous


Molecular docking, vascular endothelial growth factor receptor, Human epidermal growth factor receptor, coumarin, cancer, ADMET analysis, Phytocompounds, tyrosine kinases pathway


Objective: Cancer is the largest cause of mortality in the globe, accounting for over 10 million deaths in 2020, or roughly one in every six. Because growth factor receptors are involved in the pathophysiology of the disease in several ways, human epidermal growth factors (HER-2 and HER-3) and vascular endothelial growth factor receptors (VEGFR-2 and VEGFR-3) might be as considered therapeutic targets. coumarins and derivatives were chosen for this study to investigate their pharmacological characteristics and therapeutic effect against the targeted proteins implicated in the pathogenesis of different cancers.

Methods:  In this work, 50 coumarins and their derivatives were chosen to assess their binding affinity with the targeted proteins (HER-2, HER-3, VEGFR-2, and VEGFR-3). PyRx, a virtual tool, was utilized to perform molecular docking. The investigation was carried out computationally, with data and molecular structures of the phytocompounds and proteins derived from Indian medicinal plants, phytochemistry, and therapeutics, as well as PubChem. The protein structure was validated using a variety of tools, including PDBsum generate and BIOVIA discovery studio software. The pharmacological assessment of the ligands was carried out using ADMET filters.

Result: According to the results of molecular docking, the ligands Glycycoumarin, Mutisifurocoumarin, Thunberginol A, Pervilleanine, Licocoumarin A, and Murrayacoumarin C had the lowest binding affinity towards the four targeted proteins.

Conclusion: Since these compounds are effective against the growth factor receptors implicated in cancer pathogenesis, they could be a suitable candidate for cancer management and suppression. However, in vitro research is still required to support these findings.


Ugai T, Sasamoto N, Lee H-Y, Ando M, Song M, Tamimi RM, et al. Is early-onset cancer an emerging global epidemic? Current evidence and future implications. Nat Rev Clin Oncol [Internet]. 2022 [cited 2022 Nov 16];19(10):656–73. Available from:

Fidler MM, Gupta S, Soerjomataram I, Ferlay J, Steliarova-Foucher E, Bray F. Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012: a population-based study. Lancet Oncol [Internet]. 2017;18(12):1579–89. Available from:

Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev [Internet]. 2015;34(1):157–64. Available from:

Loibl S, Gianni L. HER2-positive breast cancer. Lancet [Internet]. 2017;389(10087):2415–29. Available from:

Vranić S, Bešlija S, Gatalica Z. Targeting HER2 expression in cancer: New drugs and new indications. Bosn J Basic Med Sci [Internet]. 2021;21(1):1–4. Available from:

Wang S-L, Zhong G-X, Wang X-W, Yu F-Q, Weng D-F, Wang X-X, et al. Prognostic significance of the expression of HER family members in primary osteosarcoma. Oncol Lett [Internet]. 2018;16(2):2185–94. Available from:

Liu X, Liu S, Lyu H, Riker AI, Zhang Y, Liu B. Development of effective therapeutics targeting HER3 for cancer treatment. Biol Proced Online [Internet]. 2019;21(1):5. Available from:

Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med [Internet]. 2013;273(2):114–27. Available from:

Klasa-Mazurkiewicz D, Jarząb M, Milczek T, Lipińska B, Emerich J. Clinical significance of VEGFR-2 and VEGFR-3 expression in ovarian cancer patients. Pol J Pathol. 2011;62(1):31–40.

Su J-L, Yen C-J, Chen P-S, Chuang S-E, Hong C-C, Kuo I-H, et al. The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer [Internet]. 2007;96(4):541–5. Available from:

Tomeh MA, Hadianamrei R, Zhao X. A review of curcumin and its derivatives as anticancer agents. Int J Mol Sci [Internet]. 2019;20(5):1033. Available from:

Nakamura K, Shimura N, Otabe Y, Hirai-Morita A, Nakamura Y, Ono N, et al. KNApSAcK-3D: a three-dimensional structure database of plant metabolites. Plant Cell Physiol [Internet]. 2013;54(2):e4. Available from:

Sayers EW, Beck J, Bolton EE, Bourexis D, Brister JR, Canese K, et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res [Internet]. 2021;49(D1):D10–7. Available from:

Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res [Internet]. 2000;28(1):235–42. Available from:

Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res [Internet]. 2018;46(W1):W296–303. Available from:

Panikar S, Shoba G, Arun M, Sahayarayan JJ, Usha Raja Nanthini A, Chinnathambi A, et al. Essential oils as an effective alternative for the treatment of COVID-19: Molecular interaction analysis of protease (Mpro) with pharmacokinetics and toxicological properties. J Infect Public Health [Internet]. 2021;14(5):601–10. Available from:

Tam B, Sinha S, Wang SM. Combining Ramachandran plot and molecular dynamics simulation for structural-based variant classification: Using TP53 variants as model. Comput Struct Biotechnol J [Internet]. 2020;18:4033–9. Available from:

Laskowski RA. PDBsum: summaries and analyses of PDB structures. Nucleic Acids Res [Internet]. 2001;29(1):221–2. Available from:

Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods Mol Biol [Internet]. 2015;1263:243–50. Available from:

Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, et al. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res [Internet]. 2021;49(W1):W5–14. Available from:

Tanno S, Ohsaki Y, Nakanishi K, Toyoshima E, Kikuchi K. Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. Lung Cancer [Internet]. 2004;46(1):11–9. Available from:

Roy PS, Saikia BJ. Cancer and cure: A critical analysis. Indian J Cancer [Internet]. 2016 [cited 2022 Nov 16];53(3):441–2. Available from:;year=2016;volume=53;issue=3;spage=441;epage=442;aulast=Roy

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature [Internet]. 2018;554(7691):189–94. Available from:

Yonesaka K. HER2-/HER3-targeting antibody-drug conjugates for treating lung and colorectal cancers resistant to EGFR inhibitors. Cancers (Basel) [Internet]. 2021;13(5):1047. Available from:

Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti- and pro-angiogenic therapies. Genes Cancer [Internet]. 2011;2(12):1097–105. Available from:

Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer [Internet]. 2013;13(12):871–82. Available from:

Wilken R, Veena MS, Wang MB, Srivatsan ES. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer [Internet]. 2011;10(1):12. Available from:

Muninggar L, Widjiati W, Yuliati I, Askandar B, Hartono P. Effects of curcumin on vascular endothelial growth factor expression on Rattus norvegicus cervical cancer xenograft model. Indonesian Journal of Cancer [Internet]. 2019 [cited 2022 Nov 16];12(3):95. Available from:

He S-D, Yang X-T, Yan C-C, Jiang Z, Yu S-H, Zhou Y-Y, et al. Promising compounds from Murraya exotica for cancer metastasis chemoprevention. Integr Cancer Ther [Internet]. 2017;16(4):556–62. Available from:

Song X, Yin S, Zhang E, Fan L, Ye M, Zhang Y, et al. Glycycoumarin exerts anti-liver cancer activity by directly targeting T-LAK cell-originated protein kinase. Oncotarget [Internet]. 2016;7(40):65732–43. Available from:

Takeuchi K, Ito F. Receptor tyrosine kinases and targeted cancer therapeutics. Biol Pharm Bull [Internet]. 2011;34(12):1774–80. Available from:



How to Cite

SHARMA, S. (2023). Molecular Docking and Interaction of Coumarin Derivatives as Inhibitors of Growth Factor Receptors. Innovare Journal of Medical Sciences, 11(2). Retrieved from



Original Article(s)